- 中枢神经系统领域的转译研究策略 -
Neuroscience and CNS drug development is experiencing a renaissance. A greater understanding of CNS related disease biology and the emergence of new, improved targets and technologies is bringing renewed interest, excitement and investment into this fascinating and potentially transformative area of medicine.
Cambridge Healthtech Institute's Translational Strategies in CNS conference focuses on one of the key issues of CNS drug development - early stage development. Key session topics include developing and validating CNS targets and biomarkers, bridging the preclinical/clinical translation gap, evaluating the strengths and weaknesses of current preclinical models, challenging "gold-standards", understanding mechanism of action, dose selection, neuroimaging, neuroinflammation, neuroimmunology, and more. 2018's meeting will focus on progress being made in the field of CNS drug development rather than historical reflection.
Day 1 | Day 2
Wednesday, June 20
11:00 am Registration Open
11:50 Bridging Luncheon Presentation: Nuclear Imaging of Neuroinflammation in Rodent Models of Neurodegenerative Diseases
Tuulia Huhtala, PhD, Head, Biomarkers and in vitro Biology, Discovery, Charles River
Activation of the mitochondrial translocator protein (TSPO) is linked to neuroinflammation, and TSPO ligands can be used for in vivo PET or SPECT imaging. In the current studies, we utilized these ligands to assess the extent of neuroinflammation after lipopolysaccharide (LPS) infusion, following induction of multiple sclerosis (MS) and neuropathic pain.
12:20 pm Dessert and Coffee Break in the Exhibit Hall with Poster Viewing
2:30 Refreshment Break in the Exhibit Hall with Poster Viewing
IMPROVING CNS TRANSLATION
3:10 Chairperson's Opening Remarks
Murali Gopalakrishnan, PhD, MBA, Senior Director, Head, Search & Evaluation Neuroscience, AbbVie
3:15 What Does Recent Clinical Data Tell Us about the Amyloid Cascade Hypothesis?
Eric Karran, PhD, Vice President, Foundational Neuroscience Center, AbbVie Neuroscience, AbbVie
The amyloid cascade hypothesis (AH) has been the predominant view of Alzheimer's disease pathogenesis. The AH in particular has informed many of the pharmacological approaches that have been tested in Phase III clinical trials, none of which has demonstrated efficacy. Given this disappointing outcome, the validity of the AH has been questioned, and this presentation will review the status of both clinical research and the AH.
3:45 Identification of Plasma Biomarkers and Therapeutic Targets for Prevention of Alzheimer's Disease
Takaomi Saido, PhD, Senior Team Leader, Proteolytic Neuroscience, Riken Brian Science Institute
For prevention of Alzheimer's disease (AD), it is necessary to diagnose preclinical AD by plasma biomarkers and to stop the progression of A pathology. Application of single App knock-in mice (Saito et al., Nat Neurosci, 2014) has enabled us to identify candidates for the biomarker and therapeutic targets. Validation of these targets will be described.
4:15 Three Essential Elements for Assessing Potential Neurotoxicity in Preparation for Submissions to FDA
Jim Baun, Vice President, Scientific Operations, NeuroScience Associates, Inc.
The ultimate endpoint of neurotoxicity is neuronal death. Detection of neurotoxicity depends on three key elements: 1) survival time after insult, 2) adequate sampling of the tissue, and 3) sensitivity of detection method. Survival time- disintegrative debris does not persist indefinitely. Sampling- the brain has over 600 populations of neurons. Detection of neuronal death- the stain to be used must be general to reveal the event regardless of cell death mechanism.
4:45 Targeting Glial Cell Pathology in Huntington's Disease with an Antibody to Semaphorin 4D
Elizabeth Evans, PhD, Vice President, Preclinical Research, Vaccinex, Inc.
Semaphorin 4D mediates glial cell activities including reactive gliosis and the survival of oligodendrocyte precursor cells that repair and remyelinate brain lesions. Preclinical target validation and development of PD biomarkers for VX15, a humanized anti-SEMA4D antibody, will be discussed. Preliminary brain imaging data from an ongoing Phase I/II clinical trial supports the hypothesis that SEMA4D antibody blockade preserves brain volume and restores metabolic activity in pre- and early-manifest HD.
5:15 Neurochemical Imaging: Connecting Basic Neuroscience to the Human Experience
Jacob M. Hooker, PhD, Phyllis and Jerome Lyle Rappaport MGH Research Scholar, Associate Professor of Radiology, Harvard Medical School
Positron emission tomography (PET) provides a window into the human brain to study chemistry provided that a radiotracer can be developed to measure molecular interactions. This presentation will describe the incredible opportunities in PET imaging and the tools that the Hooker Lab has co-developed to better realize its full potential.
5:45 Close of Day and Dinner Short Course Registration*
*Separate registration required.
Day 1 | Day 2
Thursday, June 21
7:30 am Registration Open and Morning Coffee
BIOMARKERS AND PRECLINICAL MODELS
8:00 Chairperson's Remarks
Dario Doller, PhD, Senior Director, Exploratory Science, SAGE Therapeutics
8:05 FEATURED PRESENTATION: Translatability of Early Development Proof of Principle Trials in Neurology
Johan Luthman, PhD, Vice President, Neuroscience Clinical Development, Neurology Business Group, Eisai, Inc.
Biomarkers are gaining importance as predictive biomarkers to supplement clinical outcome measures, although validation of biomarkers as surrogate outcome measures still remains a high hurdle. Alzheimer's disease (AD) is a clear illustration of how the introduction of biomarkers has entirely changed the way drug R&D is executed, but also shows the challenges of addressing remaining hurdles.
8:35 Incorporating Biomarker Endpoints in Early Clinical Development to Enable the Successful Development of Novel Neurodegenerative Therapies
Ping Chiao, PhD, Senior Director, Translational Biomarkers, Neuroscience, Biogen
This presentation will focus on preclinical discovery biomarker strategies designed to increase the successful transition of biomarkers from preclinical discovery to clinical development. As one example, the presentation will highlight studies conducted in cynomolgus monkey with BIIB076, a pan tau antibody, and the CSF pharmacokinetic and pharmacodynamic biomarker data generated. These data were critical for dose selection and sampling times in our ongoing Phase I with BIIB076.
9:05 Developing Relevant In Vitro CNS Models for Drug Discovery
Daniel Haag, PhD, CSO, NeuCyte, Inc.
NeuCyte Inc. is a biotechnology company focusing on early phases of CNS drug discovery. Based on our SynFireTM technology, we have developed a proprietary human neural in vitro platform for complex electrophysiological and morphological readouts suited for target identification and validation, efficacy testing and neurotoxicity assessment. Using patient-derived and genetically engineered defined neural cell types, NeuCyte builds unique cell-based assays for modelling neurological and neurodegenerative disorders.
9:35 Find Your Table and Meet Your Moderator
This session features various discussion groups that are led by a moderator/s who ensures focused conversations around the key issues listed. Attendees choose to join a specific group and the small, informal setting facilitates sharing of ideas and active networking.
Lost in translation? Asking the Right Questions in the Right Language
Dario Doller, PhD., Sage Therapeutics
- CNS disease etiology understanding: Who owns it?
- What are the major disconnects between lab experimentation and clinical research?
- Are differences in physiology between preclinical species and human affecting the translational gap?
- Patient segmentation: Strategies and outcomes
- Correlation or causation? Importance of genetic links for different CNS diseases
- What are the attributes that have real impact minimizing risk during novel target selection?
- Human as a model for human - What is the future of experimental medicine in CNS drug discovery?
Improving the Success Rate of CNS Therapies
Takaomi C. Saido, PhD, Laboratory Head, Laboratory for Proteolytic Neuroscience, RIKEN Brain Science Institute
- Why have more than 400 medication candidates for Alzheimer's Disease failed?
- Which therapies have the best chance to succeed, and why?
- Immunotherapy for neurodegenerative disease
- What is the future of immunotherapy?
10:20 Coffee Break in the Exhibit Hall with Poster Viewing
11:05 A New Paradigm for Therapeutic Discovery in Psychiatry
Gopi Shanker, PhD, Head of Psychiatry, Neuroscience Department, Novartis Institutes for Biomedical Research (NIBR)
Recent advances in the genetics of psychiatric disorders have led to a renewed focus on development of effective therapies in this area. However, the lack of predictive animal models continues to be a challenge for drug discovery. New advances in biomarker development through case-control as well as longitudinal studies in patients are paving the way for the development of new translational strategies and discoveries in psychiatry.
11:35 A Quantitative Pharmacology Model of Neuroactive Steroid Efficacy in Movement Disorder
David Nguyen, PhD, Principal Scientist, SAGE Therapeutics
SAGE-217 is a novel GABA-potentiator which is currently in clinical development for mood and motor related disorders. This presentation will discuss the clinical characterization of SAGE-217 from a PK/PD modeling perspective, comparing endpoints measured in Phase I related to efficacy, target engagement, and adverse events.
12:05 pm Digital Technologies for CNS Translational Studies
Brandon Farley, PhD, Senior Scientist, SAGE Therapeutics
Wearable devices can complement clinical assessments by providing continuous monitoring of movement parameters and other physiological signals, both inside and outside of the clinic. We present data from Parkinson's disease and essential tremor clinical trials which validate device-measured tremor against clinical tremor scales, and which demonstrate that devices are sensitive to pharmacological modulation of tremor. The rich pharmacodynamic datasets enabled by wearables are being employed in the development of Sage-217 and other GABAa receptor modulators for movement disorders.
12:35 Session Break
12:40 Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own
1:10 Ice Cream Break in the Exhibit Hall with Poster Viewing
NEUROINFLAMMATION AND EMERGING TARGETS
1:55 Chairperson's Remarks
Kent Werner, MD, PhD, Co-Founder and CEO, Cogentis Therapeutics; Johns Hopkins Neurology Adjunct Faculty
2:00 Targeting the Immune System to Treat Diseases of the Central Nervous System
Stevin Zorn, PhD, President and CEO, MindImmune Therapeutics, Inc.
It is increasingly clear that the central nervous system and the immune system are intimately integrated. Consequently, immune system dysfunction is a critical, often causative, factor in brain dysfunction. MindImmune are at the forefront in recognizing the therapeutic opportunities in targeting the immune system to treat brain disease.
2:30 The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases
Oleg Butovsky, PhD, Assistant Professor of Neurology, Harvard Medical School, Associate Scientist, Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital
Microglia play a pivotal role in the maintenance of brain homeostasis but lose homeostatic function during neurodegenerative disorders. In recent studies, TREM2 (triggering receptor expressed on myeloid cells 2) induced APOE signaling, and targeting the TREM2-APOE pathway restored the homeostatic signature of microglia in ALS and AD mouse models and prevented neuronal loss in an acute model of neurodegeneration. This presentation will discuss the latest work in this area.
3:00 CT-526: A Peptide Targeting CDK5 in Neurodegenerative Disease
Kent Werner, MD, PhD, Co-Founder and CEO, Cogentis Therapeutics; Johns Hopkins Neurology Adjunct Faculty
In Alzheimer's disease, CDK-5 is one of the two major kinases to phosphorylate tau and is found to be 10x more active than in cognitively normal controls - largely due to p25. Previous efforts to target CDK5 were toxic and unsuccessful. CT-526 is a peptide targeting p25 and exhibiting zero toxicity at 100x the effective dose. In multiple models, CT-526 reduces tau hyperphosphorylation, amyloid plaque formation, neuroinflammation and rescues phenotype.
3:30 From Monoclonal Antibodies to Rapastinel to Spiro-Beta-Lactam
Joseph Moskal, PhD., CSO, Aptinyx
4:00 Close of Conference
Recommended Event Package
Short Course 11: Understanding and Dealing with Drug Disposition in CNS
Conference: CNS Disease Models
Conference: Translational Strategies in CNS